Recommendation ID
NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.
Any explanatory notes
(if applicable)
Where possible, studies should consider the differential impact that pharmacokinetic dose adjustment may have on people with DPD (dihydropyrimidine dehydrogenase) deficiency, people with impaired renal or liver function, people whose body surface area is outside the standard range for dosing 5-FU and people with a less favourable performance status. Future studies might also consider the impact of DPD testing in conjunction with pharmacokinetic dose adjustment.

Source guidance details

Comes from guidance
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment
Date issued
December 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 07/01/2015